What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock?

Johnson & Johnson (NYSE: JNJ) reported new oncology data, including a 75% tumor response rate for JNJ-6143 in advanced prostate cancer. The RYBREVANT FASPRO regimen produced a 77% response rate as an initial treatment option in advanced head and neck cancer patients. ERLEADA use around surgery reduced recurrence and death risk in high risk prostate cancer, while an orthopedics merger with Smith & Nephew collapsed over leadership disagreements. The fresh JNJ-6143 and RYBREVANT FASPRO trial...